Regenerx Biopharmaceuticals Inc (RGRX) SEC Filing 8-K Material Event for the period ending Friday, September 27, 2019

Regenerx Biopharmaceuticals Inc

CIK: 707511 Ticker: RGRX

View differences made from one to another to evaluate Regenerx Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Regenerx Biopharmaceuticals Inc.


Assess how Regenerx Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Regenerx Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: RGRX
CIK: 707511
Form Type: 8-K Corporate News
Accession Number: 0001144204-19-046533
Submitted to the SEC: Mon Sep 30 2019 5:00:12 PM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Friday, September 27, 2019
Industry: Pharmaceutical Preparations
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: